PMID- 36278044
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221025
IS  - 2470-1343 (Electronic)
IS  - 2470-1343 (Linking)
VI  - 7
IP  - 41
DP  - 2022 Oct 18
TI  - Zinc Oxide Nanoparticles and Synthesized Pyrazolopyrimidine Alleviate Diabetic 
      Effects in Rats Induced by Type II Diabetes.
PG  - 36865-36872
LID - 10.1021/acsomega.2c05638 [doi]
AB  - Diabetes mellitus (DM) is a category of metabolic illness characterized by high 
      blood sugar levels and insufficient pancreatic insulin production or activity 
      within the body. The most common type of diabetes is type II diabetes, which is a 
      metabolic condition characterized by insulin resistance and pancreatic islet 
      beta-cell failure, resulting in hyperglycemia. The goal of this study was to examine 
      the anti-diabetic implications of zinc oxide nanoparticles (ZnO NPs) and/or 
      pyrazolopyrimidine in type II diabetic rats. Rats with a weight of 150 +/- 20 g 
      were used. Animals were divided into five groups as follows: group 1: control, 
      group 2: type II diabetic rats, group 3: diabetic rats received ZnO NPs (10 
      mg/kg/orally/day), group 4: diabetic rats received pyrazolopyrimidine (5 
      mg/kg/orally/day), and group 5: diabetic rats received ZnO NPs (10 
      mg/kg/orally/day) + pyrazolopyrimidine (5 mg/kg/orally/day), respectively, for 30 
      days. The results indicated that serum glucose, total cholesterol (TC), 
      triacylglycerol (TG), low-density lipoprotein-cholesterol (LDL-c), very 
      low-density lipoprotein-cholesterol (VLDL-c), malondialdehyde, alanine 
      aminotransferase (ALT), aspartate aminotransferase (AST), and peroxisome 
      proliferator-activated receptor gamma coactivator 1-alpha PGC-1alpha mRNA expressions 
      were increased in the diabetic group versus the control group, while serum 
      insulin, high-density lipoprotein-cholesterol (HDL-c), superoxide dismutase 
      (SOD), and carnitine palmitoyltransferase 1A (CPT1A) mRNA expression levels were 
      decreased. These parameters were reserved in the treated groups (ZnO NPs, 
      pyrazolopyrimidine, and ZnO NPs + pyrazolopyrimidine). This study proved that ZnO 
      NPs and pyrazolopyrimidine had an ameliorative effect on blood glucose levels, 
      antioxidant status, lipid profile, liver function enzymes, and mRNA expression of 
      hepatic genes.
CI  - (c) 2022 The Authors. Published by American Chemical Society.
FAU - Gadoa, Zahraa Alaaeldein
AU  - Gadoa ZA
AD  - Department of Chemistry, Faculty of Science, Suez Canal University in Ismailia, 
      Ismailia 41522, Egypt.
FAU - Moustafa, Ahmed Hussein
AU  - Moustafa AH
AD  - Department of Chemistry, Faculty of Science, Zagazig University, Zagazig 44519, 
      Egypt.
FAU - El Rayes, Samir Mohamed
AU  - El Rayes SM
AUID- ORCID: 0000-0003-2667-3855
AD  - Department of Chemistry, Faculty of Science, Suez Canal University in Ismailia, 
      Ismailia 41522, Egypt.
FAU - Arisha, Ahmed A
AU  - Arisha AA
AD  - Department of Animal Physiology and Biochemistry, Faculty of Veterinary Medicine, 
      Badr University in Cairo (BUC), Badr City 11829, Cairo, Egypt.
AD  - Department of Physiology, Faculty of Veterinary Medicine, Zagazig University, 
      Zagazig 44519, Egypt.
FAU - Mansour, Mohamed Fouad
AU  - Mansour MF
AD  - Department of Biochemistry, Faculty of Veterinary Medicine, Zagazig University, 
      Zagazig 44519, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20221006
PL  - United States
TA  - ACS Omega
JT  - ACS omega
JID - 101691658
PMC - PMC9583298
COIS- The authors declare no competing financial interest.
EDAT- 2022/10/25 06:00
MHDA- 2022/10/25 06:01
PMCR- 2022/10/06
CRDT- 2022/10/24 04:43
PHST- 2022/08/31 00:00 [received]
PHST- 2022/09/16 00:00 [accepted]
PHST- 2022/10/24 04:43 [entrez]
PHST- 2022/10/25 06:00 [pubmed]
PHST- 2022/10/25 06:01 [medline]
PHST- 2022/10/06 00:00 [pmc-release]
AID - 10.1021/acsomega.2c05638 [doi]
PST - epublish
SO  - ACS Omega. 2022 Oct 6;7(41):36865-36872. doi: 10.1021/acsomega.2c05638. 
      eCollection 2022 Oct 18.